After years of declining sales due to patent expiration on its megablockbuster cholesterol drug Lipitor, the company finally appears to be on a path back to reporting year-over-year growth. Investments in mergers and acquisitions deserve some credit for its improving fortune, but a lot of it also rests on fast-growing drugs churned out by its research and development team.